| 000 | 10158nam a22005053i 4500 | ||
|---|---|---|---|
| 001 | EBC5407758 | ||
| 003 | MiAaPQ | ||
| 005 | 20240724113224.0 | ||
| 006 | m o d | | ||
| 007 | cr cnu|||||||| | ||
| 008 | 240724s2018 xx o ||||0 eng d | ||
| 020 |
_a9781119305163 _q(electronic bk.) |
||
| 020 | _z9781119305149 | ||
| 035 | _a(MiAaPQ)EBC5407758 | ||
| 035 | _a(Au-PeEL)EBL5407758 | ||
| 035 | _a(OCoLC)1039079208 | ||
| 040 |
_aMiAaPQ _beng _erda _epn _cMiAaPQ _dMiAaPQ |
||
| 050 | 4 | _aRM151 .M537 2018 | |
| 082 | 0 | _a615.6 | |
| 100 | 1 | _aDonnelly, Ryan F. | |
| 245 | 1 | 0 | _aMicroneedles for Drug and Vaccine Delivery and Patient Monitoring. |
| 250 | _a1st ed. | ||
| 264 | 1 |
_aNewark : _bJohn Wiley & Sons, Incorporated, _c2018. |
|
| 264 | 4 | _c©2018. | |
| 300 | _a1 online resource (352 pages) | ||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 505 | 0 | _aCover -- Title Page -- Copyright -- Contents -- List of Contributors -- About the Editors -- Preface -- Chapter 1 Genesis of Transdermal Drug Delivery -- 1.1 Skin Anatomy -- 1.1.1 The Epidermis -- 1.1.2 The Stratum Corneum -- 1.1.3 The Dermis -- 1.1.4 Skin Appendages -- 1.2 Routes to Percutaneous Drug Absorption -- 1.3 Facilitated Transdermal Drug Delivery -- 1.3.1 Electrical-based Devices -- 1.3.1.1 Iontophoresis -- 1.3.1.2 Electroporation -- 1.3.1.3 Ultrasound -- 1.3.1.4 Cryopneumatic and Photopneumatic Technologies -- 1.3.1.5 Velocity-based Devices -- 1.3.1.6 Thermal Approaches (Lasers and Radiofrequency Heating) -- 1.3.1.7 Microneedles -- References -- Chapter 2 Microneedle Manufacturing and Testing -- 2.1 Introduction -- 2.2 Material Types, Properties and Biocompatibility -- 2.2.1 Silicon -- 2.2.1.1 Biocompatibility of Silicon -- 2.2.2 Metals -- 2.2.2.1 Biocompatibility of Metals -- 2.2.3 Ceramics -- 2.2.3.1 Biocompatibility of Ceramics -- 2.2.4 Silica Glass -- 2.2.4.1 Biocompatibility of Silica Glass -- 2.2.5 Carbohydrates -- 2.2.5.1 Biocompatibility of Carbohydrates -- 2.2.6 Polymers -- 2.2.6.1 Biocompatibility of Polymers -- 2.3 Microneedles Manufacturing and Design -- 2.3.1 Basics of Microfabrication -- 2.3.1.1 Lithography and Etching -- 2.3.1.2 Thin-film Deposition on Substrates -- 2.3.1.3 Etching -- 2.3.2 Microfabrication MNs -- 2.3.2.1 Fabrication of Silicon MNs -- 2.3.2.2 Fabrication of Metal and Glass MNs -- 2.3.2.3 Fabrication of Polymeric MNs -- 2.3.3 Microneedle Design -- 2.4 Microneedle Mechanical Characterisation -- 2.4.1 Axial Force Microneedle Mechanical Tests -- 2.4.2 Transverse Force and Shear Strength Microneedle Mechanical Tests -- 2.4.3 Baseplate Strength and Flexibility Tests -- 2.4.4 Microneedle Insertion Measurements -- 2.4.4.1 Staining of Microneedle-treated Skin -- 2.4.4.2 Transepidermal Water Loss Measurements. | |
| 505 | 8 | _a2.4.4.3 Electrical Impedance Measurements -- 2.4.4.4 Histological Tissue Staining and Sectioning -- 2.4.4.5 Confocal Microscopy -- 2.4.4.6 Optical Coherence Tomography -- 2.4.5 Significance of Microneedle Test Results -- References -- Chapter 3 Microneedle-mediated Drug Delivery -- 3.1 Introduction -- 3.2 Microneedle Drug Delivery Strategies -- 3.2.1 Solid Microneedles -- 3.2.2 Coated Microneedles -- 3.2.3 Hollow Microneedles -- 3.2.4 Dissolving Microneedles -- 3.2.5 Hydrogel-forming Microneedles -- 3.3 Conclusion -- References -- Chapter 4 Microneedle-mediated Vaccine Delivery -- 4.1 Introduction -- 4.2 Vaccine Delivery -- 4.2.1 Vaccination -- 4.2.2 Alternative Vaccine Delivery Options -- 4.3 Intradermal Vaccination -- 4.3.1 Skin Structure -- 4.3.2 Skin Immune Response -- 4.3.3 Conventional Strategies for Intradermal Vaccine Delivery -- 4.4 MN Delivery of Vaccine Therapeutics -- 4.4.1 Dissolving/Biodegrading Polymeric MNs -- 4.4.1.1 Viral Vaccines -- 4.4.1.2 Bacterial Vaccines -- 4.4.1.3 Model and Novel Vaccines -- 4.4.2 Hollow MNs -- 4.4.3 Solid MN -- 4.4.3.1 "Poke and Patch" Methodologies -- 4.4.3.2 Coated MNs -- 4.5 Future Perspectives -- References -- Chapter 5 Microneedles for Gene Therapy: Overcoming Extracellular and Intracellular Barriers -- 5.1 Gene Therapy -- 5.2 DNA Vaccination -- 5.2.1 Advantages of DNA Vaccination -- 5.2.2 Mechanism of Action of DNA Vaccines -- 5.3 Treatment of Local Skin Diseases -- 5.4 Limitations of Gene Therapy -- 5.5 Microneedles as a Physical Delivery Strategy for Gene Therapy -- 5.5.1 Solid Microneedles -- 5.5.2 Coated Microneedles -- 5.5.3 Hollow Microneedles -- 5.5.4 Dissolvable Microneedles -- 5.5.5 Microneedles in Combination with Other Delivery Technologies -- 5.5.5.1 In Combination with Physical Delivery Technologies -- 5.5.5.2 In Combination with Vector-based Delivery Technologies -- 5.6 Conclusions. | |
| 505 | 8 | _aReferences -- Chapter 6 Delivery of Nanomedicines Using Microneedles -- 6.1 Introduction -- 6.2 Skin Structure and Barrier Properties Which Impact on Nanoparticle and Microparticle Penetration -- 6.3 Conventional Nanocarriers for Topical and Transdermal Delivery -- 6.3.1 Lipidic Vesicles -- 6.3.2 Lipid Nanoparticles -- 6.3.3 Polymeric Nanoparticles and Microparticles -- 6.3.4 Microemulsions -- 6.3.5 Metallic and Mineral Nanoparticles -- 6.4 Microneedle-mediated Transdermal Delivery of Nanoparticles and Microparticles -- 6.4.1 Microneedle-assisted Nanoparticle/Microparticle Permeation -- 6.4.2 Drug Delivery -- 6.4.3 Vaccine Delivery -- 6.4.4 Other Uses -- 6.5 Conclusions -- References -- Chapter 7 Minimally-invasive Patient Monitoring and Diagnosis Using Microneedles -- 7.1 Introduction -- 7.1.1 What is Patient Monitoring? -- 7.1.2 Why is Patient Monitoring Useful? -- 7.1.3 Limitations and Challenges of Therapeutic Monitoring -- 7.2 Sampling Techniques -- 7.2.1 Minimally and Non-invasive Sample Extraction -- 7.2.2 Microneedles and Fluid Sampling Technology -- 7.3 Microneedle Fluid Extraction Device Technical Considerations -- 7.3.1 Mechanical Parameters -- 7.3.2 Fluidics -- 7.4 Microneedle Innovations -- 7.4.1 Glucose Monitoring -- 7.5 Microneedle Innovations in Analyte Monitoring -- 7.5.1 Therapeutic Drug and Biomarker Detection -- 7.6 Microneedle Electrode Technology -- 7.6.1 Electro-biochemical Monitoring -- 7.7 Sampling and Analytical Systems Integration -- 7.7.1 Limitations and Challenges Associated with Systems Integration -- 7.8 Interstitial Fluid and Blood Sampling -- 7.8.1 Devices and Patents -- 7.9 Developments Moving Forwards -- 7.9.1 Industrialisation and Commercialisation: Hurdles to Overcome -- 7.10 Conclusion -- References -- Chapter 8 Delivery of Photosensitisers and Precursors Using Microneedles -- 8.1 Introduction. | |
| 505 | 8 | _a8.1.1 Photodynamic Therapy -- 8.1.2 Photosensitisers -- 8.2 Topical Application of Photodynamic Therapy -- 8.3 Methods to Enhance Topical Photodynamic Therapy -- 8.3.1 Microneedle-mediated Photodynamic Therapy -- 8.3.2 Photodynamic Therapy and Skin Pre-treatment Using Microneedles -- 8.3.3 Delivery of Photosensitisers Using Microneedles Containing the Active Agent -- 8.4 Microneedles and Photothermal Therapy -- 8.5 Conclusion -- References -- Chapter 9 Microneedles in Improving Skin Appearance and Enhanced Delivery of Cosmeceuticals -- 9.1 Introduction -- 9.2 The Skin -- 9.3 Microneedling Technologies: An Evolutionary Step Towards MN Usage -- 9.4 Benefits of Microneedling -- 9.5 Commercially Available MN Devices -- 9.5.1 Dermaroller® -- 9.5.2 Beauty Mouse® -- 9.5.3 Dermastamp™ -- 9.5.4 Dermapen® -- 9.5.5 Light Emitting MN Devices -- 9.6 Patient Factors Relating to MN Devices -- 9.6.1 Acceptability of MN Devices by Patients and Healthcare Providers -- 9.6.2 Potential Irritation and Erythema -- 9.6.3 Patient Safety -- 9.6.4 Sterilisation Considerations -- 9.7 Delivery of Cosmeceutical Compounds -- 9.7.1 A Role for Hyaluronic Acid in MN Delivery Systems -- 9.7.2 MN-mediated Peptide Delivery -- 9.7.3 The Delivery of Other Cosmeceutical Agents -- 9.8 Recent Developments -- 9.8.1 Human Stem Cells -- 9.8.2 Fractional Radiofrequency -- 9.9 Conclusion -- References -- Chapter 10 Microneedles for Ocular Drug Delivery and Targeting: Challenges and Opportunities -- 10.1 Introduction -- 10.2 Anatomy of the Eye and Barriers to Drug Delivery -- 10.2.1 The Anterior Segment and its Barrier Function -- 10.2.2 The Posterior Segment and its Barriers Function -- 10.3 Ocular Diseases and Treatments -- 10.4 Current Ocular Drug Delivery Systems and Administration Routes -- 10.4.1 Topical Route -- 10.4.2 Oral/Systemic Administration Route -- 10.4.3 Ocular Injections. | |
| 505 | 8 | _a10.4.3.1 Anterior Segment Injections -- 10.4.3.2 Posterior Segment Injections -- 10.5 Microneedles in Ocular Drug Delivery -- 10.5.1 Hollow MNs -- 10.5.2 Solid MNs with "Coat and Poke" Strategy -- 10.5.3 Dissolving MNs -- 10.5.4 Hollow MN Strategy -- 10.5.5 Other Strategies -- 10.6 MN Application Devices -- 10.7 MN Safety Concerns -- 10.8 Conclusion -- References -- Chapter 11 Clinical Translation and Industrial Development of Microneedle-based Products -- 11.1 Introduction -- 11.2 Materials -- 11.3 Other Potential Applications -- 11.4 Patient Application -- 11.5 Patient/Healthcare Provider Acceptability -- 11.6 Patient Safety -- 11.7 Manufacturing and Regulatory Considerations -- 11.8 Commercialisation of MN Technologies -- 11.9 Conclusion -- 11.10 Future Perspectives -- References -- Index -- EULA. | |
| 588 | _aDescription based on publisher supplied metadata and other sources. | ||
| 590 | _aElectronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. | ||
| 650 | 0 | _aTransdermal medication. | |
| 650 | 0 | _aPatient monitoring-Equipment and supplies. | |
| 655 | 4 | _aElectronic books. | |
| 700 | 1 | _aSingh, Thakur Raghu Raj. | |
| 700 | 1 | _aLarrañeta, Eneko. | |
| 700 | 1 | _aMcCrudden, Maeliosa T. C. | |
| 776 | 0 | 8 |
_iPrint version: _aDonnelly, Ryan F. _tMicroneedles for Drug and Vaccine Delivery and Patient Monitoring _dNewark : John Wiley & Sons, Incorporated,c2018 _z9781119305149 |
| 797 | 2 | _aProQuest (Firm) | |
| 856 | 4 | 0 |
_uhttps://ebookcentral.proquest.com/lib/orpp/detail.action?docID=5407758 _zClick to View |
| 999 |
_c2522 _d2522 |
||